Guyer William's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Dec 3, 2025
- Accession no.
- 0001193125-25-307282
- Filed
- Dec 3, 2025
- Trade date
- Dec 1-2, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.60M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Guyer WilliamCIK 0001879013 | Officer (Chief Development Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2025 | Common Stock | AGrant or awardAcquired | +224 | $79.78F2 | +$17,870.72 | 224 | Direct | |
| Dec 1, 2025 | Common Stock | AGrant or awardAcquired | +224 | $0.00 | $0 | 448 | Direct | |
| Dec 2, 2025 | Common Stock | GGiftDisposed | −787 | $0.00 | $0 | 0 | Indirect | |
| Dec 2, 2025 | Common Stock | JOtherAcquired | +787 | $0.00 | $0 | 1,235 | Direct | |
| Dec 2, 2025 | Common Stock | MOption exerciseAcquired | +20,000 | $21.65 | +$433,000 | 21,235 | Direct | |
| Dec 2, 2025 | Common Stock | SSaleDisposed | −19,360 | $80.05F7 | −$1,549,768 | 1,875 | Direct | |
| Dec 2, 2025 | Common Stock | SSaleDisposed | −640 | $80.88 | −$51,763.2 | 1,235 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 2, 2025 | Common Stock | MOption exerciseDisposed | −20,000 | $0.00 | $0 | 270,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Referenced by the price of 1 transaction in Table I.
- F7
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.78 to $80.68 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
The power of attorney under which this form was signed is on file with the Commission.